Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: patlawche11 who wrote (47502)	11/28/2018 10:10:00 AM
From: patlawche11	10 Recommendations of 63285

Phase III Ascent Trial for TNBC updated last week (Nov. 21, 2018). What's notable is the number of new study locations open and now recruiting outside of the US, specifically Canada - 2 new locations, France - 9 new locations, Germany - 5 new locations, Spain - 1 new location, and the UK - 8 new locations. I seem to recall Michael Pehl saying awhile back that once IMMU132 is approved in the US, they expect recruitment to significantly drop off in the US and that recruitment outside of the US will provide much of the additional patients required to complete the study. Hopefully a good sign! clinicaltrials.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next